
    
      Phase I/IIa, open-label, 3 + 3 multi-dose escalation study. The Phase I part of the study was
      to include the dose escalation cohort; a conventional dose escalation design, following 3 + 3
      rules was chosen to define the MTD.

      The Phase IIa part was to include the MTD/recommended phase II dose (RPTD) expansion cohort
      in which descriptive statistical methods for evaluation of response, time to event endpoints,
      and safety were to be performed.

      35 subjects in the Safety population, 34 subjects in the ITT and PP populations.
    
  